Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B
Authors:
- Renuka RajuRRRenuka Raju
- Sujai SuneethaSSSujai Suneetha
- Rupendra S JadhavRJRupendra S Jadhav
- MeherVani ChaduvulaMCMeherVani Chaduvula
- Sara AtkinsonSASara Atkinson
- Suman JainSJSuman Jain
- Leo H VisserLVLeo H Visser
- Loretta DasLDLoretta Das
- Ravindra PanhalkarRPRavindra Panhalkar
- Vidyagouri ShindeVSVidyagouri Shinde
- Parphananda P ReddyPRParphananda P Reddy
- Pramila BarkatakiPBPramila Barkataki
Open Access
- 28 July 2014
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 13 (1) , 119
Abstract
Corticosteroids have been extensively used in the treatment of immunological reactions and neuritis in leprosy. The present study evaluates the serological response to steroid treatment in leprosy reactions and neuritis. Seven serological markers [TNF-α, antibodies to Phenolic glycolipid-1 (PGL-1 IgM and IgG), Lipoarabinomannan (LAM IgG1 and IgG3), C2-Ceramide and S100 B] were analyzed longitudinally in 72 leprosy patients before, during and after the reaction. At the onset of reaction these patients received a standard course of prednisolone. The levels of the above markers were measured by Enzyme linked immunosorbent assay (ELISA) and compared with the individuals own value in the month prior to the reaction and presented as percentage increase. One month before the reaction individuals showed a varying increase in the level of different markers such as TNF-α (53%) and antibodies to Ceramide (53%), followed by to PGL-1 (51%), S100B (50%) and LAM (26%). The increase was significantly associated with clinical finding of nerve pain, tenderness and new nerve function impairment. After one month prednisolone therapy, there was a fall in the levels [TNF-α (60%), C2-Ceramide (54%), S100B (67%), PGL-1(47%) and LAM (52%)] with each marker responding differently to steroid. Reactions in leprosy are inflammatory processes wherein a rise in set of serological markers can be detected a month before the clinical onset of reaction, some of which remain elevated during their action and steroid treatment induces a variable fall in the levels, and this forms the basis for a variable individual response to steroid therapy.Keywords
This publication has 26 references indexed in Scilit:
- Comparing the Clinical and Histological Diagnosis of Leprosy and Leprosy Reactions in the INFIR Cohort of Indian Patients with Multibacillary LeprosyPLOS Neglected Tropical Diseases, 2012
- Leprosy now: epidemiology, progress, challenges, and research gapsThe Lancet Infectious Diseases, 2011
- Increased CXC Ligand 10 Levels and Gene Expression in Type 1 Leprosy ReactionsClinical and Vaccine Immunology, 2011
- Analysis of Antibody and Cytokine Markers for Leprosy Nerve Damage and Reactions in the INFIR Cohort in IndiaPLOS Neglected Tropical Diseases, 2011
- Predicting Neuropathy and Reactions in Leprosy at Diagnosis and Before Incident Events—Results from the INFIR Cohort StudyPLOS Neglected Tropical Diseases, 2009
- Effects of Prednisolone Treatment on Cytokine Expression in Patients with Leprosy Type 1 ReactionsInfection and Immunity, 2005
- Glucocorticoids and the Th1/Th2 BalanceAnnals of the New York Academy of Sciences, 2004
- Immunohistochemical Analysis of Cellular Infiltrate and Gamma Interferon, Interleukin-12, and Inducible Nitric Oxide Synthase Expression in Leprosy Type 1 (Reversal) Reactions before and during Prednisolone TreatmentInfection and Immunity, 2001
- Risk factors for type-1 reactions in borderline leprosy patientsThe Lancet, 1991
- The Glomerular Permeability Determined by Dextran Clearance Using Sephadex Gel FiltrationScandinavian Journal of Clinical and Laboratory Investigation, 1968